A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

Zhu, Haiyan; Tian, Yian; Cheng, Huaiping; Zheng, Yafei; Wang, Wei; Bao, Ting; Wu, Rongqian; Tian, Zengshan

doi:10.7150/ijms.58650

Cited by 3 publications

(2 citation statements)

References 38 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It also identified magenta modules in which BPD was positively associated. These modules contained autophagy-regulated genes (S100a8, COL17A1, CD69, BASP1, SIGLEC5, CA1), which are linked to BPD progression, with S100a8 being involved in the immune process of BPD inflammation counteracting [50]. Thus, represents an indicator of plasma inflammation in children with BPD.…”

Section: Methods Validationmentioning

confidence: 99%

Identification of biomarkers of bronchopulmonary dysplasia by single cell transcriptome sequencing technology and WGCNA：Data from bioinformatics analysis

Li,

Huang

2023

Preprint

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a disease of chronic lung dysfunction. We combined Weighted Gene Co-expression(WGCNA) and single-cell RNA analysis (scRNA-seq) to identify the biomarkers linked to BPD. Two data were obtained by searching the Gene Expression Omnibus (GEO) database with corresponding keywords, GSE190934 and GSE188944, the former for scRNA-seq and the latter for WGCNA. In the GSE190934 data, 10,762 differential genes showed up, with S100a9, S100a8, and Lyz2 being expressed primarily in pericytes. We have found that S100a8 was found to be significantly higher in the hyperoxia model mice. While Ccl5 was mainly located in CD4+ T cells, Ccl4 was mainly expressed in myeloid cells. In addition, the data has revealed that Emp2 is regarded as a marker of type I alveolar cells in BPD. Among the enriched signaling pathways by the GSE188944, several signaling communications were found to exhibit high expression patterns in BPD. The bioinformatics analysis identified some key genes and cellular communication components of BPD. These findings provide insights into the cellular and molecular underpinning of BPD pathological mechanisms.

show abstract

Section: Methods Validationmentioning

confidence: 99%

Identification of biomarkers of bronchopulmonary dysplasia by single cell transcriptome sequencing technology and WGCNA：Data from bioinformatics analysis

Li,

Huang

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Xác định được cơ chế bệnh sinh ở mức độ phân tử giúp xác định rõ vai trò của các dấu ấn sinh học, giúp đưa ra được các chẩn đoán rõ ràng hơn vì các dấu ấn sinh học này có thể dễ dàng định lượng được. Từ đây hứa hẹn sẽ cung cấp tiền đề để xây dựng các liệu pháp điều trị nhắm trúng đích, ví dụ một nghiên cứu gần đây đánh giá lợi ích của việc sử dụng dấu ấn sinh học (LRP1 và S100A8) để quyết định và đánh giá hiệu quả của liệu pháp dexamethasone76 .…”

unclassified

Changes in definition and pathogenesis of bronchopulmonary dysplasia in preterm infants: A review

Nguyễn,

Dương,

Nguyễn

2022

Sci.Tech.Dev.J.-HealthSci.

View full text Add to dashboard Cite

Bronchopulmonary dysplasia (BPD) is a common complication in preterm neonates, especially extremely preterm. However, effective prevention strategies and treatment methods are still being explored. Although the concept of BPD emerged a few decades ago, a consensus definition has not been established globally yet. The syndrome of BPD was introduced by Northway in 1967. With constant changes and improvements in newborn care and understanding about its pathogenesis, the definition of BPD has been changing and updated accordingly. NICHD (National Institute of Child Health and Human Development) first published the classification of BDP severity based on the level of required oxygen in 2001. Seventeen years later, in 2018, a new grading system was proposed to include new ventilation support methods. Unified diagnosis criteria and severity classification are important to facilitate consistent diagnosis between centers. Besides, understanding of BPD pathogenesis suggests antenatal risk factors such as genetic factors, intrauterine growth restriction, pre-eclampsia, inflammation, smoking during pregnancy; as well as postnatal risk factors such as oxygen toxicity, inflammation, moderate to large patent ductus arteriosus. Identification of these risk factors provides evidence for more effective treatment methods. This review describes the evolution of definitions, influence of lung development on BPD, and pathogenesis factors associated with BPD.

show abstract

Salivary cortisol is not associated with dexamethasone response in preterm infants with evolving bronchopulmonary dysplasia

Lewis,

Jensen,

Courtney

et al. 2024

J Perinatol

View full text Add to dashboard Cite

A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants

Cited by 3 publications

References 38 publications

Identification of biomarkers of bronchopulmonary dysplasia by single cell transcriptome sequencing technology and WGCNA：Data from bioinformatics analysis

Identification of biomarkers of bronchopulmonary dysplasia by single cell transcriptome sequencing technology and WGCNA：Data from bioinformatics analysis

Changes in definition and pathogenesis of bronchopulmonary dysplasia in preterm infants: A review

Salivary cortisol is not associated with dexamethasone response in preterm infants with evolving bronchopulmonary dysplasia

Contact Info

Product

Resources

About